logo
CanyamAI summaries for academic research
language
MobileMobile
  • Phone FeatureWeChat Mini Program
EnglishEnglish
noticeNotice
BlogBlog
delete
arrow
Back
B

Bruce E. Sands

icahn school of medicine at mount sinai

107H-index
1.1KPaper Count
6.5WCitation Count
Published Papers 375
Publication Date
logo
IOIBD: the International Organization for the Study of Inflammatory Bowel Disease
errTherapeutic Advances in Gastroenterology
IF3.4
err2026-08-02
err0
PREAI
errIris Dotan; Marla C. Dubinsky; Corey A. Siegel; James Lindsay; Dermot McGovern; Matthieu Allez; Pär Myrelid; James Lewis; Bruce E. Sands; Laurent Peyrin-Biroulet; Silvio Danese; Vineet Ahuja; Gilaad G. Kaplan; Marischka Konings; Richard Gearry; Siew C. Ng; Vipul Jairath; Fernando Magro; Mark S. Silverberg; Dan Turner; Maria T. Abreu; Ailsa Hart; Axel Dignass; David T. Rubin;
errShare
errSave
Subcutaneous infliximab in the treatment of patients with perianal fistulizing Crohn’s disease: current evidence and emerging roles
errTherapeutic Advances in Gastroenterology
IF3.4
err2026-07-21
err0
PREAI
errAxel Dignass; Catherine Reenaers; Anthony Buisson; Fernando Magro; Lucine Vuitton; Soyeon Park; Meoung Jun Park; Bruce E. Sands
errShare
errSave
Recommendations for the Evaluation and Management of Inflammatory Bowel Disease with Irritable Bowel Syndrome-Like Symptoms: A Joint Rome Foundation and International Organization for the Study of IBD (IOIBD) Consensus
errGastroenterology
IF25.1
err2026-04-29
err0
errOAAI
errChristopher Ma; Alexander C. Ford; Jana G. Hashash; Giovanni Barbara; Charles N. Bernstein; Darren M. Brenner; Anne M. Griffiths; Laurie Keefer; Millie D. Long; Samuel Nurko; Prashant Singh; Bruce E. Sands; Lin Chang
errShare
errSave
Impact of Immunogenicity on Clinical Outcomes in Patients With Moderate-to-Severe Inflammatory Bowel Disease Receiving Subcutaneous Infliximab: A Post Hoc Analysis of the LIBERTY Trials
errUnited European Gastroenterology Journal
IF6.7
err2026-04-15
err0
errOAAI
errJean-Frédéric Colombel; Silvio Danese; Stefan Schreiber; Bruce E. Sands; Andres J. Yarur; Aram Kang; Dong-Hyeon Kim; Young Nam Lee; Stephen B. Hanauer
errShare
errSave
Symptom Response Dynamics for Personalised Therapy with Subcutaneous Infliximab in Crohn’s Disease: Insights from the Randomised, Placebo-Controlled, Phase 3 LIBERTY-CD Trial
errAdvances in Therapy
IF4
err2026-03-30
err0
errOAAI
errStefan Schreiber; Bruce E. Sands; Silvio Danese; Edward V. Loftus; Ae Lee Jeong; Dong-Hyeon Kim; Young Nam Lee; Jean-Frédéric Colombel
errShare
errSave
Mirikizumab Long-Term Efficacy and Safety in Patients with Crohn’s disease: Results from the VIVID-2 Open-Label Extension Trial
errClinical Gastroenterology and Hepatology
IF12
err2026-03-05
err0
errOAAI
errBruce E. Sands; Edward L. Barnes; Geert D’Haens; Tadakazu Hisamatsu; Miguel Regueiro; Colleen R. Kelly; David Laharie; Rebecca R. Hozak; Guanglei Yu; Arul Gandhi R; Michelle U. Lopes; Frederick Durand; Marijana Protic; Richard E. Moses; Severine Vermeire
errShare
errSave
Efficacy and Safety of Obefazimod in Patients With Moderately to Severely Active Ulcerative Colitis: Results From Two, Phase 3, Randomised, Double-Blind, Placebo-Controlled, 8-Week Induction Trials (ABTECT-1 and 2)
errAMERICAN JOURNAL OF GASTROENTEROLOGY
IF7.6
err2025-12-01
err0
PREAI
errSands, Bruce E.; Danese, Silvio; Peyrin-Biroulet, Laurent; Dubinsky, Marla; Hisamatsu, Tadakazu; Tilg, Herbert; Atreya, Raja; Armuzzi, Alessandro; Treton, Xavier; Baert, Filip; Seidler, Ursula; Cataldi, Fabio; Jacobstein, Doug; Rabbat, Christopher J.; Shan, Kejia; Duvall, George Aaron; Siegmund, Britta; Dulai, Parambir S.; Rubin, David; Vermeire, Severine
errShare
errSave
Wearable devices detect physiological changes that precede and are associated with symptomatic and inflammatory rheumatoid arthritis flares
errScientific Reports
IF3.9
err2025-11-30
err0
errOAAI
errPragya Sharma; Matteo Danieletto; Jessica K. Whang; Kyle Landell; Drew Helmus; Bruce E. Sands; Mayte Suarez-Farinas; Percio S. Gulko; Robert P. Hirten
errShare
errSave
Endoscopic response to subcutaneous infliximab by disease location: A post hoc analysis of the LIBERTY-CD study
errClinical Gastroenterology and Hepatology
IF12
err2025-11-22
err0
PREAI
errBruce E. Sands; Stefan Schreiber; Marla C. Dubinsky; Geert D’Haens; Bincy P. Abraham; Miguel Regueiro; Silvio Danese; Hyunsoo Park; Dong-Hyeon Kim; Young Nam Lee; Stephen B. Hanauer; Jean-Frédéric Colombel
errShare
errSave
Serum protein profiles differ with adalimumab and ustekinumab treatment in moderately to severely active Crohn's disease
errJOURNAL OF CROHNS & COLITIS
IF8.7
err2025-11-01
err0
PREAI
errVenkat, Swati; Zeeman, Martha; Hart, Amy; Bhagat, Sunita; Galbraith, David A.; Hoops, Timothy; Ufberg, Paul J.; Izanec, James; Freeman, Tom C.; Mcrae, Bradford; Shinzaki, Shinichiro; Jairath, Vipul; Panaccione, Remo; Sands, Bruce E.; Branigan, Patrick
errShare
errSave
Design and rationale for the VICTRIVA study: A randomized, double-blind, phase 3b study of vedolizumab in combination with upadacitinib in Crohn's disease
errCONTEMPORARY CLINICAL TRIALS COMMUNICATIONS
IF1.4
err2025-11-01
err0
errOAAI
errDanese, Silvio; Sands, Bruce E.; Feagan, Brian G.; Jairath, Vipul; Panaccione, Remo; Peyrin-Biroulet, Laurent; Irving, Peter M.; Schreiber, Stefan; Dotan, Iris; Ferrante, Marc; D'haens, Geert R.; Jones, Stephen; Freire, Marcelo; Lindner, Dirk; Adsul, Shashi; Oberai, Pooja; Colombel, Jean-Frederic
errShare
errSave
Case 31-2025: A 56-Year-Old Man with Left Lower Abdominal Pain and Anemia
errNEW ENGLAND JOURNAL OF MEDICINE
IF78.5
err2025-10-30
err0
PREAI
errSands, Bruce E.; Shenoy-Bhangle, Anuradha S.; Lemieux, Jacob E.; Johnson, P. Connor; Nkosi, Dingani
errShare
errSave
Impact of Prior Biologic Exposure on Ozanimod Efficacy and Safety in the Phase 3 True North Clinical Trial
errAMERICAN JOURNAL OF GASTROENTEROLOGY
IF7.6
err2025-10-01
err2
PREAI
errSands, Bruce E.; Rubin, David T.; Loftus, Edward V.; Wolf, Douglas C.; Panaccione, Remo; Colombel, Jean-Frederic; Dignass, Axel; Regueiro, Miguel; Vermeire, Severine; Afzali, Anita; Lawlor, Garrett; Ahmad, Harris A.; Wu, Hsiuanlin; Osterman, Mark T.; Jain, Anjali; D'Haens, Geert
errShare
errSave
Guselkumab Pharmacokinetics and Exposure-Response Relationships Are Consistent Following Intravenous vs Subcutaneous Induction in Participants With Crohn's Disease
errAMERICAN JOURNAL OF GASTROENTEROLOGY
IF7.6
err2025-10-01
err0
PREAI
errD'Haens, Geert R.; Adedokun, Omoniyi J.; Yang, Tae E.; Sands, Bruce E.; Danese, Silvio; Terry, Nat A.; Olurinde, Mobolaji; Van Rampelbergh, Rian; Vetter, Marion L.; Hisamatsu, Tadakazu; Panaccione, Remo
errShare
errSave
Establishing a multiple outcome set for Crohn's disease in real-world evidence studies: results from a Delphi e-survey
errJOURNAL OF CROHNS & COLITIS
IF8.7
err2025-10-01
err0
PREAI
errMoreira, Paula Leao; Dignass, Axel; Estevinho, Maria Manuela; Santiago, Mafalda; Reinisch, Walter; Sands, Bruce E.; D'haens, Geert; Mantzaris, Gerassimos J.; Danese, Silvio; Peyrin-Biroulet, Laurent; Dotan, Iris; Jairath, Vipul; Magro, Fernando
errShare
errSave
Baseline Characteristics Associated With Probability of Remission and Greater Absolute Benefit of Treatment With Afimkibart (RO7790121/RG6631)
errAMERICAN JOURNAL OF GASTROENTEROLOGY
IF7.6
err2025-10-01
err0
PREAI
errAllegretti, Jessica R.; Peyrin-Biroulet, Laurent; Danese, Silvio; Dulai, Parambir S.; Banerjee, Anindita; Chandra, Deepa E.; Peeva, Elena; Neelakantan, Srividya; Vincent, Michael S.; Hung, Kenneth; Ursos, Lyann; Schiffman, Courtney; Bojic, Daniela; Lasch, Karen; Sands, Bruce E.
errShare
errSave
Mirikizumab Provides Sustained Long-Term Efficacy Up to 4 Years of Treatment for Ulcerative Colitis: Final Results From the LUCENT-3 Open-Label Extension Study
errAMERICAN JOURNAL OF GASTROENTEROLOGY
IF7.6
err2025-10-01
err0
PREAI
errSands, Bruce E.; Clemow, David B.; D'Haens, Geert R.; Vermeire, Severine; Irving, Peter M.; Kobayashi, Taku; Peyrin-Biroulet, Laurent; Samaan, Karen; Gaur, Anil; Paulissen, Jerome; Folian, Sarah; Arora, Ravneet; Paquette, Nicholas; Moses, Richard E.; Dignass, Axel
errShare
errSave
Maintenance of Endoscopic and Histologic Efficacy With Guselkumab for Ulcerative Colitis at Week 92 of the QUASAR Long-Term Extension Study
errAMERICAN JOURNAL OF GASTROENTEROLOGY
IF7.6
err2025-10-01
err0
PREAI
errHisamatsu, Tadakazu; Panes, Julian; Magro, Fernando; Lichtenstein, Gary R.; Allegretti, Jessica R.; Bressler, Brian; Afif, Waqqas; Samaan, Mark A.; Ye, Byong Duk; Yarandi, Shadi; Germinaro, Matthew; Shipitofsky, Nicole; Pandya, Dwiti; Miao, Ye; Zhang, Hongyan; Dignass, Axel; Sands, Bruce E.
errShare
errSave
Disease duration impacts intestinal gene expression profiles in Crohn's disease but not in ulcerative colitis
errJOURNAL OF CROHNS & COLITIS
IF8.7
err2025-10-01
err0
PREAI
errIbing, Susanne; Tastad, Christopher; Renard, Bernhard Y.; Cohen, Louis J.; Argmann, Carmen; Helmus, Drew; Schadt, Eric E.; Merad, Miriam; Kukreja, Anjli; Visvanathan, Sudha; Sands, Bruce E.; Dubinsky, Marla; Suarez-Farinas, Mayte; Colombel, Jean-Frederic; Bottinger, Erwin P.; Cho, Judy H.; Petralia, Francesca; Ungaro, Ryan C.
errShare
errSave
Asthma remission in the context of other immune-mediated diseases
errJournal of Allergy and Clinical Immunology
IF11.2
err2025-09-29
err0
errOAAI
errJosef Smolen; Bruce E. Sands; Daniel J. Jackson; Michael E. Wechsler; David J. Jackson; Praveen Akuthota; Flavia Cecilia Lega Hoyte; Ian Pavord; Rohit K. Katial; Linda Rogers
errShare
errSave

Research Directions

No research directions
Co-authors
Cooperation Journals
W
William J. Sandborn
H-index: 199 · Papers: 2.1K
S
Stefan Schreiber
H-index: 192 · Papers: 1.9K
H
Håkon Håkonarson
H-index: 177 · Papers: 1.5K
J
Jerome I. Rotter
H-index: 176 · Papers: 1.8K
S
Séverine Vermeire
H-index: 163 · Papers: 2.4K
View more